Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office ...

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar ...

Fortune Brands Innovations has leased the majority of the former Horizon Therapeutics headquarters as relocates employees from other cities to the northern suburb.

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.